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Abstract
Winning entry to the Student Voice 2019. The article focuses on a personal encounter that I had as a medical
student when I was sent off to ‘study’ a patient with a rare disease who had been admitted to hospital.
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‘No Friends 1’
Patients with rare diseases, particularly those with ‘use-
ful’ signs for medical students, are often a hot commodity
when inpatients in hospital. Supervisors dispatch us with a
bed number and instructions to report our findings back
to them, so we trot dutifully to far-flung wards with our
stethoscopes slung around our necks, mentally reciting
our spiel as we go;
‘Hi my name is Annie and I’m one of the fifth-year
medical students … ’
David was one such patient. I was told to examine his
peripheral nervous system, and as I headed towards his
room I wondered what might be wrong with him. His date
of birth, scribbled in my notebook along with his name
and hospital number, suggested he was only 23. Cerebral
Palsy? Muscular dystrophy? It was week two of my neur-
ology rotation, and I’d mostly examined elderly people
with strokes thus far, so I wasn’t sure what to expect.
David looked up and sighed ruefully as I entered his
side room, putting his book down and giving me an
amused smile.
‘Let me guess – a fifth year medical student on your
neurology rotation? And you’d like to examine me?’
Thrown by this role reversal, I stared at him mutely,
and nodded.
‘Annie’ I managed.
‘That’s fine, although just to let you know you’re the
fourth one this morning, and it’s only 10:30’
I apologised, and made to leave, but he grinned and
beckoned me inside, so I drew the curtain and nervously
washed my hands, glancing surreptitiously at him. He
was very thin, with dark brown hair cropped brutally
short. His skin was so white as to be almost translucent
- except that it was scattered with large pigmented areas
the colour of tea with too much milk. They were every-
where, emerging from the sleeves of his hospital gown,
climbing up the side of his neck, and bisecting his fore-
head. I tried not to stare, so looked around the sparse
room, noticing his side table piled high with books, and
a walking frame in the corner.
David was a model patient for examining, as he knew
the examination routine better than I did. I found that
he had leg weakness on both sides, with brisk reflexes
and no sensation below his umbilicus. He also had some
weakness and sensory loss in his left arm, which suggested
a C6 radiculopathy (a compression of the nerve exiting the
spinal cord). In combination with the pigmented areas of
skin (usually known as café-au-lait macules), I was fairly
sure he had neurofibromatosis type 1, and that his neuro-
logical symptoms were being caused by nerve sheath tu-
mours or meningiomas in his spine.
Neurofibromatosis type 1 (NF1) is a syndrome caused
by a mutation in the NF1 gene. One of many related con-
ditions known as RASopathies, it has a has a panoply of
possible manifestations, from the eponymous neurofibro-
mas, to rarer symptoms such as cataracts and arterial
stenosis [1]. Neurological development can be impaired,
resulting in intellectual disability, and it increases the like-
lihood of multiple cancers. Life expectancy is not greatly
reduced, but quality of life is lower in both children and
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adults than control groups, particularly with more morbid
manifestations such as dystrophic scoliosis. It affects 1/
3000 people, making it one of the commonest genetic syn-
dromes in the world.
David confirmed that he had NF1 (‘or as I call it, No
Friends 1’), including multiple spinal tumours, and con-
gratulated me slightly sardonically on my deductions. I sat
down to take a history, and he looked confused.
‘Ah. You’re the first one who’s wanted a chat’
I was surprised, and saddened. How awful it must have
been to be David, constantly prodded and gawked at by
medical students (most of whom were around his age),
but unable to actually have a conversation with any of
them. David was an expert patient, but I quickly realised
that I’d prefer to hear about how NF1 had affected him
than a disease summary I could learn from google.
‘So, how are you doing? Mentally, rather than
physically?’
I watched as David’s eyes filled with tears, which he
wiped embarrassedly on the blanket. It became apparent
that in the 8 days since his admission, no one had asked
him how he was dealing with the mental burden of his
condition – something which is all too common for rare
disease patients. In a survey conducted by Rare Disease
UK [2], 46% of patients, and 58% of their carers report
never being asked about their mental health/wellbeing.
This is despite the well-established impact that living
with a rare disease has on patients’ mental health. A
meta-analysis of studies on the quality of life (QoL) of
rare disease patients from 2010 showed that of the 58
studies included, a majority found that rare diseases
patients had poorer quality of life [3]. Fourteen studies
found that psychosocial quality of life was diminished in
comparison with healthy controls, even if physical qual-
ity of life was not. The mental burden of living with a
chronic illness should not be underestimated.
Furthermore, poor mental health is a comorbid factor
in patients with chronic health conditions, worsening
outcomes and quality of life [4]. Studies have shown that
this effect is often worse in children and young people
affected with a chronic condition – they feel more
acutely the loss of their current (or future) functioning
than older adults [5]. As most rare diseases affect young
people [6], it seems evident that this is a population in
need of more mental health support than others. How-
ever, this need goes largely unmet. Whilst patients are
well supported physically by multidisciplinary teams,
these often lack a psychiatric or psychological input, par-
ticularly in the UK, where mental health provisions are
underfunded and inadequate in many areas [7].
Patients with NF1 are no exception. Multiple studies
have shown poorer QoL in NF1 patients and carers than
unaffected controls [8, 9], and psychosocial measures of
QoL are particularly affected [8]. David had been on an-
tidepressants since he was 17, and had had panic attacks
since he was 7, usually triggered by anxiety about future
manifestations of his condition. Now that he was bed-
bound, he told me he thought about suicide nearly every
day, but didn’t feel like he could talk to anyone about it,
particularly his parents. He was part of an NF1 forum
on Facebook, but had stopped looking at it, as it made
him angry to see people his age with NF1 who weren’t
as profoundly disabled as he was. As he put it:
‘ This tumour is shredding my nerves day by day,
both literally and figuratively’
David’s distress and frustration are shared by many rare
disease patients. Studies have shown that loneliness [10],
lack of social support [11], disempowerment, uncertainty
about the future [12], and feelings of blame or loss [13]
are all associated with feelings of depression and anxiety
in rare disease patients.
Clinicians are capable of both exacerbating and ameli-
orating patients’ psychological distress, in all settings
from GP to inpatient care. A patient’s GP making an
effort to learn about a condition rather than relying on
the patient for information alleviates somewhat the
burden of responsibility that many patients feel for their
own healthcare provision [2]. Similarly, specialists re-
membering to enquire about patients’ psychosocial well-
being as well as their physical symptoms helps patients
feel heard. Whilst individual changes in practice do little
to eliminate the systemic change that needs to take place
around provision of mental health services, they can
make an enormous difference to patients.
Secondly, as was recommended by Rare Diseases UK
in their report on mental health and rare diseases,
healthcare professionals should signpost patients to
sources of support. Patient support groups and charities
exist for many rare diseases, and there are broader
groups available for patients without a specific charity
for their condition. Whilst these charities cannot always
provide professional mental health support, talking to
other patients or carers facing similar challenges can
help reduce loneliness and uncertainty.
The biggest change, however, must occur at a national
level. Both main parties have pledged to increase mental
health funding should they win the 2019 general elec-
tion. Whilst this is a welcome and necessary change, for
rare disease patients it is not enough. The way we
approach rare diseases must change, so that mental
health assessment and treatment is commonplace, and a
standard part of rare disease management. This will be
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difficult to implement, and requires coordinated engage-
ment from every medical speciality, as well as from the
NHS at an organisational level.
Talking to David taught me a lot about the kind of doc-
tor I aspire to be. It can be easy to conflate a person with
a pathology, but in doing so we lose sight of a fundamen-
tal truth – that our patients are first and foremost human
beings. They crave conversation and human connection,
just like the rest of us. I hope that my fellow future doc-
tors and I will always remember to put ourselves in our
patients’ shoes, and to ask a simple question:
‘How are you doing today?’
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